An original pharmaceutical product – Larifan (Lariphan) is developed at the Latvian Academy of Sciences and at present is produced at Larifāns Ltd (Larifan Ltd). Larifan is a patented, double-stranded RNA (dsRNA) of natural origin obtained from bacteriophage-infected E.coli cells.

Larifan possesses various biological activities like interferon – inducing immunomodulating, antiviral, antitumoral and antimutagenic properties. These activities are a result of the action of the induced endogenous interferon, but they also may be provoked directly by the dsRNA molecule. Currently, there are various product forms available, all of which contain the active ingredient dsRNS Larifan in varying concentrations.